Name : Hussein OsmanAmmar

Date and Place of Birth:15.6.1943, Menia, Egypt.

Occupation:

  • Chairman, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt.
  • Professor of Pharmaceutical Technology, Department of Pharmaceutical Technology, National Research Centre, Dokki, Cairo, Egypt.

1948 – 1952Student, primary school

1952 – 1956Student, preparatory school

1956 – 1959Student, secondary school

1959 – 1964Undergraduate student, Faculty of Pharmacy, CairoUniversity

1964 – 1965Pharmacist, Improvement and Development Department,Chemical Industries Development Inc.

1965 – 1970Research Associate, Department of Pharmaceutical Sciences, National Research Centre, Cairo as well as postgraduatestudent, Faculty of Pharmacy,CairoUniversity.

1968Obtained M. Pharm. Degree in Pharmacy (Pharmaceutics), grade excellent, CairoUniversity, on the basis of a thesis entitled “A Study of Certain Technological Aspects Concerning the Stability of InjectableL- Ascorbic Acid Solutions”

1970Obtained Ph.D. Degree in Pharmaceutical Sciences (Pharmaceutics),CairoUniversity, on the basis of a thesis entitled “A contribution to the Solubility and Stability of Riboflavine”

1971 – 1976Research Staff Member, Department of Pharmaceutical Sciences, National Research Centre

1976 – 1981Associate Research Professor, Department of Pharmaceutical Sciences, National Research Centre, Cairo

1976 – 1980Teaching, undergraduate students, Pharmaceutical Technology and Physical Pharmacy, Faculty of Pharmacy,AssiutUniversity

1976 – 1980Teaching, Postgraduate Students, Physical Pharmacy, Faculty of Pharmacy,AssiutUniversity

1976Postdoctoral Grant, British Royal Society, School of Pharmacy, Manchester University, U.K.

1981 till nowProfessor of Pharmaceutical Technology, National Research Centre

1987 – 2005Co-chairman, Scientific Permanent Committee of Pharmaceutical Sciences, National Research Centre

1991 – 1995Vice-Dean, Pharmaceutical Industries Research Division National Research Centre

1994 till now Active Member, New YorkAcademy of Sciences

1995 – 1997Chairman, Department of Pharmaceutical Sciences, National Research Centre

1995 Scientific Mission, Academy of Sciences, Czech Republic.

1996Biographee, Who’s Who in the World, 14 th edition.

1997 – 2000Chairman, Pharmaceutical Industries Research Division, National Research Centre

2001 – 2008 Teaching, undergraduate students, Pharmaceutical Technology and Physical Pharmacy, Faculty of Pharmacy,Suez – CanalUniversity

2001 – 2008 Teaching, postgraduate students, Physical Pharmacy, Faculty of Pharmacy,Suez – CanalUniversity

2007Teaching undergraduate students, Pharmaceutics and Physical Pharmacy, Faculty of Pharmacy, 6th October University

2007 – 2009Chairman, Department of Pharmaceutical Technology, National Research Centre

2008 till nowTeaching, undergraduate students, Pharmaceutical Technologyand Clinical Pharmacy, Faculty of Pharmacy, Future University

2012 till nowChairman, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University

Teaching Experience:

1976 – 1980Teaching, undergraduate students, Pharmaceutical Technology and Physical Pharmacy, Faculty of Pharmacy, AssiutUniversity

1976 – 1980Teaching, Postgraduate Students, Physical Pharmacy, Faculty of Pharmacy, AssiutUniversity

2001 till nowTeaching, undergraduate students, Pharmaceutical Technology and Physical Pharmacy, Faculty of Pharmacy, Suez – Canal University

2001 till nowTeaching, postgraduate students, Physical Pharmacy, Faculty of Pharmacy, Suez – CanalUniversity

2007Teaching undergraduate students, Pharmaceutics and Physical Pharmacy, Faculty of Pharmacy, 6th October University

2008 till nowTeaching undergraduate students, Pharmaceutical Technology and Clinical Pharmacy, Faculty of Pharmacy, Future University

Participation in Research Projects:

  1. Principal Investigator, Research Project financed by Academy of Scientific Research and Technology, entitled “Studies on the Bioavailability of Drugs under Local Conditions” (1984 – 1987).
  1. Co-principal Investigator, Research Project financed by Academy of Scientific Research and Technology, entitled “Rubber Articles for Medical and Pharmaceutical Uses” (1984 – 1987).
  1. Consultant, Project no. 4 – 13 – 43, Bilharsiasis National Research Project,Ministry of Public Health - AID (1991 – 1994).
  1. Principal Investigator, Research Project financed by Academy of Scientific Research and Technology, entitled "A study on the Bioavailability of Selected Drugs and Reasons for their Unstability" (1995 – 1998).
  1. Principal Investigator, Mega Project financed by National Research Centre, entitled "Application of Nanotechnology for Delivering and Improving the Therapeutic Efficacy of Selected Drugs” (2008 – 2010).
  1. Principal Investigator, Research Project financed by Ministry of Trade and Industry and Ministry of Higher Education and State for Scientific Research, entitled "Development of a drug delivery system for administration of insulin by oral route" (2008 – 2010).

Participation in International Conferences:

  1. Third European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, Germany (1987).
  2. 47th Congress of Pharmaceutical Sciences of FIP, Amsterdam, TheNetherlands (1987).
  3. 5th International Conference on Pharmaceutical Technology, Paris, France (1989).
  4. Fourth European Congress of Biopharmaceutics and Pharmacokinetics, Geneva, Switzerland (1990).
  5. 54th Congress of Pharmaceutical Sciences of FIP, Lisbon, Portugal (1994).
  6. 57th Congress of Pharmaceutical Sciences of FIP, Vancouver, Canada (1997).
  7. 7th Commonwealth Pharmaceutical Association Conference and Pharmacy Australian Congress, Melbourne, Australia (1999).
  8. 60th Congress of Pharmaceutical Sciences of FIP, Vienna, Austria (2000).
  9. 61st Congress of Pharmaceutical Sciences of FIP, Singapore (2001).
  10. British Pharmaceutical Conference, Manchester, U.K. (2004).
  11. 65th Congress of Pharmaceutical Sciences of FIP, Cairo, Egypt (2005).
  12. XIII International Cyclodextrin Symposium, Torino, Italy (2006).
  13. British Pharmaceutical Conference, Manchester, U.K. (2006).
  14. 1st International Conference on Drug Design & DiscoveryDubai, UAE (2008).
  15. 15thInternational Cyclodextrin Symposium, Vienna, Austria (2010).

Publications:Two patents, 6 patents (under review) and 110 scientific research papers.

Prizes:

  1. Awarded the First Class Medal for Science and Arts by President of the Arab Republic of Egypt (2013).
  2. Awarded the Golden Medal of the Academy of Scientific Research and Technology (2013).
  3. Awarded the Appreciation State Prize in the realm of Advanced Technological Sciences ״Medical Sciences״ (2010).
  4. Awarded the National Research Centre Prize for Scientific Appreciation (2009).
  5. Awarded the Scopus Award for Scientific Contribution to Pharmacology (2008).
  6. Awarded the National Research Centre Prize for Scientific Distinction (1994).

Thesis Supervision:19 M. Pharm. Theses and 10 Ph.D. Theses.

International Activities:

  1. Active Member, New YorkAcademy of Sciences.
  2. Reviewer, Discovery and Innovation.
  3. Reviewer, Drug Development and Industrial Pharmacy.
  4. Reviewer, Journal of Inclusion Phenomena and Macrocyclic Chemistry.
  5. Reviewer, Current Drug Delivery.
  6. Reviewer,Expert opinion on Drug Metabolism and Toxicology.
  7. Reviewer,Recent Patents on Drug Delivery and Formulation.
  8. Reviewer, International Journal of Pharmaceutical Sciences.
  9. Reviewer,Asian Journal of Pharmaceutical Sciences.
  10. Reviewer, Journal of Carbohydrate Polymers.
  11. Reviewer, Journal of Current Nanoscience.
Prof. Dr. Hussein OsmanAmmar
List of Publications

I. Scientific papers

(1969)

  1. On heavy metal ions contamination from ampoule glass.

Kassem, M.A., Kassem, A.A. and Ammar, H.O., Pharm. ActaHelv.44, 535.

  1. Studies on the stability of injectable L-ascorbic acid solutions.

I. Effect of pH, solvent, light and container.

Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 44, 611.

  1. Studies on the stability of injectable L-ascorbic acid solutions.

II. Effect of metal ions and oxygen content of solvent water.

Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 44, 667.

(1972)

  1. Studies on the stability of injectable L-ascorbic acid solutions.

III. Effect of metal complexing agents.

Kassem, M.A., Kassem, A.A. and Ammar, H.O., ibid. 47, 89.

(1975)

  1. Studies on the stability of injectable solutions of some phenothiazines.

I. Effect of pH and buffer systems.
Ammar, H.O., Salama, H.A. and El-Nimr, A.E.M., Pharmazie30, 368.

  1. Studies on the stability of injectable solutions of some phenothiazines.

II. Effect of chelating agents and antioxidants.
Ammar, H.O., El-Nimr, A.E.M. and Salama, H.A., ibid. 30, 369.

(1976)

  1. Stability of injection solutions of vitamin B1.

I. Influence of chelating agents.

Ammar, H.O., ibid. 31, 235.

  1. Stability of injection solutions of vitamin B1.

II. Influence of lipoic acid.

Ammar, H.O., ibid. 31, 373.

  1. On the solubilization properties of surfactant-polymer complexes.

Ammar, H.O., ibid. 31, 784.

10. On the rheology of polyoxyethylenesorbitol lanolin derivatives.

Salama, H.A., Ammar, H.O. and El-Nimr, A.E.M., FetteSeifenAnstrichmittel78, 317.

11. On the influence of liquid derivatives of lanolin on the rheology of hydrocarbon ointmentbases.

Salama, H.A., El-Nimr, A.E.M. and Ammar, H.O., ibid. 78, 319.

(1977)

12. On the dissolution and bioavailability of phenindione.

I. Phenendione tablets.

Ammar, H.O., Kassem, M.A., Salama, H.A. and El-Ridy, M.S., Pharm. Ind. 39, 171.

13. On the dissolution and bioavailability of phenindione.

II. Dissolution rate of phenindione powder and solid dispersions.

Salama, H.A., Kassem, M.A., Ammar, H.O. and El-Ridy, M.S., ibid. 39, 290.

14. On the dissolution and bioavailability of phenindione.

III. Dissolution and bioavailability of phenindione capsules.

Kassem, M.A., Salama, H.A., Ammar, H.O. and El-Ridy, M.S., ibid. 39, 396.

15. Interaction between thiamine hydrochloride and lipoic acid.

Ammar, H.O. and Salama, H.A., Pharmazie32, 34.

16. Effect of beeswax on the rheological characteristics of soft paraffin.

Salama, H.A and Ammar, H.O., FetteSeifenAnstrichmittel79, 154.

17. A paper chromatographic method for separation and determination of synephrinein injectable solutions.

El-Nimr, A.E.M., Ammar, H.O. and Salama, H.A., Pharmazie32, 402.

(1979)

18. Rheological studies on Macaloid dispersions.

I. Effect of preservatives.

Salama, H.A. and Ammar, H.O., Pharm. Ind.41, 89.

19. Effect of some hydrotropic agents on the water solubility of aminophenazone.

Ibrahim, S.A., Ammar, H.O., Kassem, A.A. and Abu- Zaid, S.S., Pharmazie34,809.

(1980)

20. On the dissolution of digoxin.

Kassem, M.A., Ammar, H.O., Salama, H.A. and El-Ridy, M.S., Pharm. Ind.42, 757.

21. Solubilizingbenzothiadiazide diuretics by Cetomacrogol 1000.

Ammar, H.O. and Salama, H.A., ibid. 42, 849.

22. Solubility of chlorothiazide and hydrochlorothiazide in mixed aqueous solvent system

Ibrahim, S. A., Ammar, H.O. and El-Faham, T.H., Proc. 2nd Intern. Pharm. Conf. Pharm. Technol., Paris, France, June 3-5.

23. Interaction of aromatic monocarboxylic acid derivatives with amidopyrine.

Ammar, H.O., Ibrahim, S.A., Kassem, A.A. and Abu- Zaid, S. S., Pharm. Ind. 42, 1312.

24. Studies on some factors affecting stability of isoniazid solutions.

I. Effect of pH - value and buffer system.

Ibrahim, S.A., Ammar, H.O. and Abd El- Mohsen, M.G., Bull. Pharm. Sci., AssiutUniversity3, 25.

(1981)

25. Effect of alcohols on the rheological characteristics of Macloid dispersions.

Salama, H.A. and Ammar, H.O., Pharmazie36, 15.

26. Effect of polyvinylpyrrolidone on the rheological characteristics of Macloid dispersions.

Salama, H.A. and Ammar, H.O., ibid. 36, 262.

27. Interaction between bendroflumethiazide and caffeine.

Ammar, H.O. and Salama, H.A., ibid. 43, 265.

28. Effect of sodium salts of toluic acids on the water solubility of riboflavine.

Ammar, H.O. and Salama, H.A., Pharm. Ind.43, 194.

29. Interaction of chlorothiazide and hydrochlorothiazide with certain amides, imides andxanthines.

Ammar, H.O., Ibrahim, S.A. and El- Faham, T.H., ibid. 43, 292.

30. On the dissolution of chlorothiazide powders and solid dispersions.

Salama, H.A., Ammar, H.O., Kassem, M.A. and El-Ridy, M. S., ibid. 43, 1242.

(1982)

31. Effect of aromatic hydrotropes on the solubility of some benzothiadiazines.

Ammar, H.O., Ibrahim, S.A. and El- Faham, T.H., Pharmazie37, 36.

32. Effect of chelating agents on the stability of inectableisoniazid solutions.

Ibrahim, S.A., Ammar, H.O. and Abd El- Mohsen, M.G., ibid. 37, 272.

33. On the dissolution of chlorothiazide and hydrochlorothiazide tablets and capsules.

Ammar, H.O., Kassem, M.A., Salama, H.A. and El-Ridy, M.S., Bull. Nat. Res. Centre, Egypt7, 75.

34. On the dissolution of hydrochlorothiazide powders and solid dispersions.

Kassem, M.A., Salama, H.A., Ammar, H.O. and El-Ridy, M.S., Pharm. Ind.44, 1186.

35. Complex formation between antihistaminic drugs and caffeine.

Mattha, A. G., Ammar, H.O., Abdel-Samie, M., El-Nahhas, S.A. and Kassem, M.A.,

Pharm. Acta.Helv.57, 268.

(1983)

36. Interaction of pheothiazines and caffeine.

I. Complex formation.

Ammar, H.O., Mattha, A.G., Abdel-Samie, M., El-Nahhas, S.A. and Kassem, M.A.,ibid. 58, 23.

37. Interaction of pheothiazines and caffeine.

II. Effect of complexation with caffeine on the stability and in-vitro transport of phenohiazines.

Abdel- Samie, M., Ammar, H.O., Mattha, A.G., El-Nahhas, S.A. and Kassem, M.A., ibid. 58, 28.

(1989)

38. Solubilizing of glucocorticoids with cetomacrogol.

Ammar, H.O. and Omar , S.M., Pharm.Ind.51, 1450.

(1991)

39. Interaction of pheothiazines with xanthines.

I. Interaction of pheothiazineswith caffeine.

Ammar, H.O., Elmahrouk, G., Omar, S.M., El-Nahhas, S.A. and Kassem, M.A., ibid. 53, 786.

40. Interaction of pheothiazines with xanthines.

II. Interaction of phenothiazineswith theophylline.

Elmahrouk, G., Ammar, H.O., Omar, S. M., El-Nahhas, S.A. and Kassem, M.A., ibid.53, 868.

41. Interaction of pheothiazines with xanthines.

III. Effect of complexation with xanthines on the bioavailability of chlorpromazine.

Ammar, H.O., Omar, S. M., El-Nahhas, S.A. and Kassem, M.A., ibid. 53, 959.

(1992)

42. Interaction of glucocorticoids with xanthines.

Ammar, H.O., El-Nahhas, S. A., Omar, S. M. and Khalil, R. M., Egypt.J. Pharm. Sci.33, 981.

(1993)

43. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

I. Prednisolone tablets.

Ammar, H.O., Khalil, R. M. and Omar, S. M., Pharmazie48, 57.

44. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

II. Paracetamol tablets.

Ammar, H.O. and Khalil, R.M., ibid. 48, 129.

45. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

III. In vitro/in vivo correlation for paracetamol tablets.
Ammar, H.O. and Khalil, R.M., ibid. 48, 136.

46. Effect of aromatic hydrotropes on the solubility of allopurinol.

I. Effect of sodium salts of hydroxy and amino derivatives of benzoic acid.

Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 436.

47. Effect of aromatic hydrotropes on the solubility of allopurinol.

II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and nicotinic acids.

Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 534.

48. Effect of aromatic hydrotropes on the solubility of allopurinol.

III. Effect of sodium salts of toluic acids.

Ammar, H.O. and El-Nahhas, S.A., ibid. 48, 751.

49. Effect of aromatic hydrotropes on the solubility of phenacetin.

I. Effect of sodium salts of hydroxy and amino derivatives of benzoic acid.

Ammar, H.O. and Khalil, R.M., ibid. 48, 842.

50. Effect of aromatic hydrotropes on the solubility of phenacetin.

II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and nicotinic acids.

Ammar, H.O., Omar, S.M. and Khalil, R. M., ibid. 48, 845.

51. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

IV. Chloropromazine hydrochloride tablets.

Ammar, H.O., Omar, S.M. and Khalil, R. M., ibid. 48, 927.

52. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

V. In vitro/in vivo correlation for chlorpromazine hydrochloride tablets.
Ammar, H.O., Khalil, R.M. and Omar, S.M., ibid. 48, 932.

(1994)

53. Evaluation of antischistosomal effect of praziquantel in a liposomal delivery system.

Ammar, H.O., El- Ridy, M.S., Ghorab, M. and Ghorab, M.M., Int. J. Pharm. 103, 237.

54. Interaction of allopurinol with phenylephrine and certain analgesics.

Ammar, H.O., El-Nahhas, S.A., Omar, S. M. and Khalil, R.M., J. Drug Res., Egypt 21, 65.

55. Solubilization ofbromhexine hydrochloride by non -ionic surfactants.

Ammar, H.O. and El-Nahhas, S.A., Pharmazie49, 583.

56. Effect of aromatic hydrotropes on the solubility of carbamazepine.

I. Effect of sodium salts of hydroxy and amino derivatives of benzoic acid.

Ammar, H.O. and Omar, S.M., Egypt. J. Pharm. Sci. 35 ,189.

57. Effect of aromatic hydrotropes on the solubility of carbamazepine.

II. Effect of nicotinamide and sodium salts of benzoic, naphthoic and nicotinic acids.

Ammar, H.O. and Omar, S.M., ibid. 35, 209.

58. Solubilization of carbamazepine hydrochloride by non -ionic surfactants.

Ammar, H.O. and Omar, S.M. ,Pharmazie49, 746.

59. Solubiliztion of allopurinol with methyl xanthines.

Ammar, H.O., El-Nahhas, S.A., Khalil, R.M. and Omar, S.M. ibid. 49,839.

(1995)

60. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

I. Allopurinol.
Ammar, H.O. and El-Nahhas, S.A., ibid.50, 49.

61. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

II. Colchicine.
Ammar, H.O. and El-Nahhas, S.A., ibid.50, 269.

62. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

III. Bromhexine hydrochloride.
Ammar, H.O. and El-Nahhas, S.A., ibid. 50, 408.

63. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

IV. Chlorpromazine hydrochloride.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab, M.M., ibid. 50, 805.

(1996)

64.Effect of aromatic hydrotropes on the solubility of oxamniquine.

I. Effect of sodium salts of hydroxy and amino derivatives of benzoic acid.

Ammar, H.O. and Khalil, R.M., ibid. 50, 809.

65. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

V. Theophylline.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab, M. M., ibid. 51, 42.

66. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

VI. Ampicillin.

Ammar, H.O., El-Nahhas, S.A. and Ghorab, M.M., ibid. 51, 568.

67. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

VI. Rifampicin.

Ammar, H.O. and Khalil, R.M., ibid. 51, 165.

68. Effect of aromatic hydrotropes on the solubility of oxamniquine.

II. Effect of nicotinamide and sodium salts of benzoic, naphthoic, nicotinic and isonictinic acids.

Ammar, H.O. and Khalil, R.M., ibid. 51, 490.

69. Solubilization of certain analgesics by Cetomacrogol 1000.

Ammar, H.O. and Khalil, R.M., Egypt. J. Pharm. Sci. 37, 261.

70. Interaction of dicumarol with β- cyclodextrin.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab, M.M., ibid.37, 431.

71. Interaction of hydrochlorothiazide with β- cyclodextrin.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A., Omar, S.M. and Ghorab, M.M., ibid. 37, 445.

(1997)

72. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method.

VII. Aspirin.

Ammar, H.O., El-Nahhas, S.A., Emara, L.H., Ghorab, M.M. and Salama, H.A., Pharmazie52, 145.

73. Improvement of some pharmaceutical properties of drugs by cyclodextrincomplexation.

VII. Trimethoprim.

Ammar, H.O., El-Nahhas, S.A. and Emara, L.H., ibid. 52, 376.

74. Improvement of the biological performance of oral anticoagulant drugs.

I. Warfarin.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A. and Makram, T.S., ibid. 52, 627.

75. Improvement of the biological performance of oral anticoagulant drugs.

II. Dicumarol
Ammar, H.O., Ghorab. M., El-Nahhas, S.A. and Makram, T.S., ibid. 52, 727.

76. Preparation and evaluation of sustained – release solid dispersions of drugs with Eudragit polymers.

Ammar, H.O. and Khalil, R.M., Drug Devel. Ind. Pharm. 23, 1043.

77. Interaction of oral anticoagulants with methyl xanthines.

Ammar, H.O., Ghorab, M., El-Nahhas, S.A. and Makram, T.S., Pharmazie52, 946.

78. Dissolution rate as a predictory tool for assessing comparative bioavailability of generic ampicillin capsules.

Ammar, H.O., El-Nahhas, S.A. and Khalil, R.M., Egypt.J.Pharm. Sci. 38, 527.

(1998)

79. Cyclodextrin in acetazolamide eye drops formulations.

Ammar, H.O., El- Nahhas, S.A. and Khalil, R.M., Pharmazie53, 559.

80. Liposomal delivery systems in hydrocortisone eye drops formulation.

Salama, H.A., Ammar, H.O. and Khalil, R. M., Egypt.J.Pharm. Sci. 39, 19.

81. Liposomal delivery systems in timololmaleate eye drops formulation.

Salama, H. A., Ammar, H.O. and Khalil, R. M., ibid. 39, 109.

(1999)

82. Inclusion complexation of furosemide in cyclodextrins.

I. Effect of cyclodextrins on the physicochemical characteristics of furosemide.

Ammar, H.O., Ghorab, M., Emara, L.H., El- Nahhas, S.A. and Makram, T.S., Pharmazie54, 142.

83. Inclusion complexation of furosemide in cyclodextrins.

II. Implication on bioavailability.

Ammar, H.O., Ghorab, M., Emara, L.H., El- Nahhas, S.A. and Makram, T.S., ibid.,54, 207.

(2000)

84.Design of slow – release furosemide.

Ammar, H.O., Ghorab, M., El- Nahhas, S.A. and Makram, T.S., Pharmacy World Congress 2000, Vienna, Austria 26 – 31 August.

(2001)

85.Design of dexamethazone eye drops with prolonged effect.

Ammar, H.O., Salama, H.A., Ghorab, M., El- Nahhas, S.A. and Elmotasem, H., Pharmacy World Congress 2001, Singapore 1 – 6 September.

(2004)

86.A transdermal delivery system for glipizide.

Ammar, H.O., Salama, H.A., Ghorab, M., El- Nahhas, S.A. and Elmotasem, H., J. Pharm. Pharmacol.56, S - 41.

(2005)

87.Design and evaluation of prednisolone acetate eye drops with prolonged effect.

Ammar, H.O., Salama, H.A., Ghorab, M., El - Nahhas, S.A. and Elmotasem, H., Egypt.J.Pharm. Sci. 46, 9.

88.A transdermal delivery system for aspirin as an antithrombotic drug.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. and Kamel, R., British Pharmaceutical Conference, Manchester, U.K.

(2006)

89.Formulation and biological evaluation ofglimepiride–cyclodextrin–polymer systems.

Ammar, H.O.,Salama,H.A.,Ghorab, M. andMahmoud,A.A., Int. J. Pharm.309,129.

90. Implication of inclusion complexation of glimepirideincyclodextrin–polymer systems on its dissolution,stability and therapeutic efficacy. Ammar, H.O.,Salama,H.A.,Ghorab, M. andMahmoud,A.A., ibid.,320, 53.

91. A Transdermal Delivery System for Glipizide.

Ammar, H.O., Salama, H.A., Ghorab, M., El –Nahhas, S.A.andElmotasem, H., Current Drug Delivery, 3, 333.

92.Design of a transdermal delivery system for aspirin as an antithrombotic drug.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A.andKamel, R., Int. J. Pharm.,327, 81.

(2007)

93. Inclusion Complexation of Glimepiride in Dimethyl-β-Cyclodextrin.

Ammar, H.O., Salama, H.A., Ghorab, M. and Mahmoud, A.A., Asian Journal of Pharmaceutical Sciences, 2, 44.

  1. Physicochemical and biological evaluation of chemical penetration enhancers for transdermal delivery of aspirin.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A.andKamel, R., ibid.,2, 96.

  1. Nanoemulsions for delivering warfarintransdermally.

Ammar, H.O., Salama, H.A., Ghorab, M., El - Nahhas, S.A. and El Feky, G.S., 1st Conferance on Material Sciences and Nanonotechnology “Future Challenges”,National Research Centre, Cairo, Egypt.

  1. Extended release of tramadol hydrochloride using polymeric matrix system viatransdermal route.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. and Kamel, R., 1st Conferance on Material Sciences and Nanonotechnology “Future Challenges”,National Research Centre, Cairo, Egypt.

(2008)

97. Design and evaluation of chitosan films for transdermal delivery of glimepiride.

Ammar, H.O.,Salama, H.A., El-Nahhas, S.A., and Elmotasem, H., Current Drug Delivery,5, 290.

98.Polymeric matrix system for transdermal delivery of tramadol hydrochloride.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., 1st International Conference on Drug Design & Discovery, February 4-7, Dubai, UAE.

(2009)

99.Polymeric matrix system for prolonged delivery of tramadol hydrochloride, Part I: Physicochemical evaluation.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., AAPS PharmSciTech, 10, 7.

100. Polymeric matrix system for prolonged delivery of tramadol hydrochloride, Part II: Biological evaluation.

Ammar, H.O., Ghorab, M., El - Nahhas, S.A. andKamel, R., ibid.10, 1065.

  1. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride.

Ammar, H.O., Salama, H.A., Ghorab, M. andMahmoud, A.A., AAPS PharmSciTech, 10, 808.